Xiong Cai

Discovery of 7-(4-(3-Ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-<i>N</i>-hydroxyheptanamide (CUDC-101) as a Potent Multi-Acting HDAC, EGFR, and HER2 Inhibitor for the Treatment of Cancer

Xiong Cai, Hai-Xiao Zhai, Jing Wang et al. · Journal of Medicinal Chemistry · 2010 · 264 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +15

Cancer Network Disruption by a Single Molecule Inhibitor Targeting Both Histone Deacetylase Activity and Phosphatidylinositol 3-Kinase Signaling

Changgeng Qian, Cheng-Jung Lai, Rudi Bao et al. · Clinical Cancer Research · 2012 · 241 citations

Medicine, Oncology, Pharmacology +15

CUDC-101, a Multitargeted Inhibitor of Histone Deacetylase, Epidermal Growth Factor Receptor, and Human Epidermal Growth Factor Receptor 2, Exerts Potent Anticancer Activity

Cheng-Jung Lai, Rudi Bao, Xu Tao et al. · Cancer Research · 2010 · 212 citations · Full text

Medicine, Oncology, Pharmacology +17

CUDC-305, a Novel Synthetic HSP90 Inhibitor with Unique Pharmacologic Properties for Cancer Therapy

Rudi Bao, Cheng-Jung Lai, Hui Qu et al. · Clinical Cancer Research · 2009 · 112 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +10

Cellular succinate metabolism and signaling in inflammation: implications for therapeutic intervention

Hong Huang, Gejing Li, Yini He et al. · Frontiers in Immunology · 2024 · 111 citations · Full text

Life Sciences, Biochemistry, Immunology +17